<html>
  <head>
    <title>form8k.htm</title>
<!-- Licensed to: Sonfield & Sonfield-->
<!-- Document Created using EDGARizer 4.0.4.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="left"><a name="eolPage1" /><a name="FIS_TOP_OF_DOCUMENT" /><a name="DEEP_8K_010808_HTM" /><a name="FIS_FORM"><br></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><a name="CER8K7104_HTM"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman, serif">SECURITIES
AND EXCHANGE COMMISSION</font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Washington,
D.C. 20549</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 18.25pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 18.25pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman, serif">FORM
8-K</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">CURRENT
REPORT</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">PURSUANT
TO SECTION 13 OR 15 (D)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">of
the</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">SECURITIES
EXCHANGE ACT OF 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman Bold, serif">Date
of Event Reported: February 5, 2008</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman Bold, serif">Date
of Submission: February 6, 2008</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 20.5pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 20.5pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman Bold, serif">INTEGRATED
MEDIA HOLDINGS, INC.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">(Exact
name of registrant as specified in its charter)</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">DELAWARE</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">(State
or other jurisdiction of incorporation or organization)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">
            <tr>
              <td valign="top" width="36%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 12.55pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif">33-119586</font></div>
              </td>
              <td valign="top" width="36%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">76-0600966</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="36%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">(<font style="DISPLAY: inline; FONT-SIZE: 11pt">Commission File
      Number)</font></font></div>
              </td>
              <td valign="top" width="36%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><font style="DISPLAY: inline; FONT-SIZE: 11pt">(IRS Employer Identification
      Number</font>)</font></div>
              </td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">William
L. Sklar</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">President</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Integrated Media Holdings,
Inc</font>.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">12000
Westheimer, Ste 340</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Houston,
TX 77077-6531</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">&#160;(Address
of principal executive offices)</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">281-600-6000
Ext 105</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">&#160;(Registrant&#8217;s
telephone number, including area code)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 0pt"><br></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
        <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br>
          <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
            <div id="FTR">
              <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
            </div>
            <div id="PN" style="PAGE-BREAK-AFTER: always">
              <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
              <div style="WIDTH: 100%; TEXT-ALIGN: center">
                <hr style="COLOR: black" noshade size="2">
              </div>
            </div>
            <div id="HDR">
              <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
            </div>
          </div><br></div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="left"><a name="eolPage2" /><a name="FIS_SECTION_2_FINANCIAL_INFORMATION" /><a name="FIS_CHANGE_IN_ASSETS"><br></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">ITEM
2.01 &#8211;Acquisition or Disposition of Assets</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>On February 5, 2008, Integrated Media
Holdings, Inc. announced that it had signed a definitive merger agreement to
combine with TeleChem International, Inc.(&#8220;TeleChem&#8221;).&#160;&#160;TeleChem
International is a privately held, Inc. 500 company with diversified business
activities in the life sciences, chemical trading and disease diagnostics
areas.&#160;&#160;As a result of the merger, the shareholders of TeleChem (the
&#8220;TeleChem Shareholders&#8221;) will own a majority of the voting stock of Integrated
Media, that will change its name to Arrayit Corporation.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The merger agreement provides that the
shareholders of Telechem International, Inc. will be issued thirty five (35)
million common shares that represent 64.95% of the outstanding common after
taking into account: (i) a 1:30 reverse split approved by the directors and
majority shareholders, (ii) conversion of all outstanding shares of preferred
stock, (iii) conversion of all outstanding debt obligations of Integrated Media;
and (iv) the shares underlying a recently issued warrant to purchase 1,250,000
shares of common stock.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><a name="FIS_FINANCIAL_OBLIGATION_MATERIAL">TELECHEM</a></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Description
of the Company</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">TeleChem
is a privately-held company that was founded in 1993 by Rene Schena and Todd
Martinsky as a chemical import and export trading company.&#160;&#160;TeleChem&#8217;s
chemicals division provides customers with the raw materials required for
plastics, water soluble fertilizers, and alternative fuels.&#160;&#160;After
four years of operations in the chemicals market, TeleChem entered the
biotechnology sector with the creation of the ArrayIt&#174; Life Sciences Division in
1996.&#160;&#160;Because of the public interest in the Human Genome Project and
microarray technology, TeleChem focused on microarray products and services for
the research, pharmaceutical and diagnostics markets.&#160;&#160;TeleChem&#8217;s
ArrayIt&#174; Division currently provides its patented microarray platform (US
6,101,946) to more than 3,000 installations serving an estimated 10,000
laboratories, making it the most widely used microarray technology in the
world.&#160;&#160;Supporting instruments, kits, reagents, and hardware complete
the ArrayIt&#174; line of more than 400 products making up what management believes
is a universal microarray platform for any type of biomolecule.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">During
the year 2001, the Diagnostics Division was started in order to leverage the
patented (6,913,879) multi-patient technology for genetic screening and
testing.&#160;&#160;This next generation microarray format allows clinical
laboratories to examine tens of thousands of patients on a single microarray,
providing much more cost-effective gene information for population-wide
diagnostics than traditional &#8220;single patient&#8221; microarrays.&#160;&#160;The
company is currently developing or has developed tests for many major human
diseases including cystic fibrosis, sickle cell anemia, and
cancer.&#160;&#160;ArrayIt intends to compete in the $20 billion molecular
diagnostics arena.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">The
TeleChem customer base includes major universities, pharmaceutical and biotech
companies, agricultural and chemical companies, government agencies, national
research foundations and private sector enterprises around the
world.&#160;&#160;The company website receives more than 1,000,000 hits per
month and the Shopping Cart allows on-line product ordering 24 hours a day. The
website makes available the Electronic Library free-of-charge to the tens of
thousands of researchers worldwide that wish to keep pace with the microarray
literature. TeleChem scientists were featured on NOVA&#8217;s television show
&#8220;Cracking the Code of Life&#8221; in 2001.&#160;&#160;The company received the Rising
Star Award from the City of Sunnyvale in 2002 and 2003, the Silicon Valley Top
50 Award from the San Jose Business Journal in 2003, and consecutive selection
to the Inc. 500 List in 2002 and 2003 by Inc. magazine.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">TeleChem&#8217;s
principal office is in Sunnyvale, California.&#160;&#160;TeleChem presently has
eight (8) employees.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.1pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.1pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Proposed
Executive Officers and Directors After the Acquisition</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.1pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="68%">
            <tr>
              <td valign="top" width="23%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif"><font style="DISPLAY: inline">NAME</font></font></div>
              </td>
              <td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif"><font style="DISPLAY: inline">AGE</font></font></div>
              </td>
              <td valign="top" width="67%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif"><font style="DISPLAY: inline">POSITION</font></font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="67%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="23%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif">Rene&#8217;
      A. Schena</font></div>
              </td>
              <td valign="top" width="10%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif">44</font></div>
              </td>
              <td align="left" valign="top" width="67%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif">Chairman
      , Director, President &amp; CEO</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="67%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="23%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif">Todd
      J. Martinsky</font></div>
              </td>
              <td valign="top" width="10%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif">42</font></div>
              </td>
              <td align="left" valign="top" width="67%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif">Vice
      President &amp; Director</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="67%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="23%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif">Mark
      Schena, Ph.D.</font></div>
              </td>
              <td valign="top" width="10%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif">44</font></div>
              </td>
              <td align="left" valign="top" width="67%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif">Chief
      Technology Officer, Secretary &amp; Treasurer</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="67%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td valign="top" width="23%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif">Paul
      Haje</font></div>
              </td>
              <td valign="top" width="10%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif">52</font></div>
              </td>
              <td align="left" valign="top" width="67%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman, serif">Director
      of Advertising and Public Relations</font></div>
              </td>
            </tr>
            <tr>
              <td valign="top" width="23%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
              <td valign="top" width="67%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
            </tr>
        </table>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic; FONT-FAMILY: Times New Roman Bold, serif">Ms.
Schena</font> holds a degree in Language Studies from the University of
California Santa Cruz. She has 23 years experience in international business,
including translation, contract documentation and commodities trading with a
subsidiary of ConAgra from 1985 to 1988, and as a chemical import and
distribution specialist, department manager, and later President of NuSource
Chemical Corporation.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">She
founded TeleChem International, Inc. in 1993, continuing the import and export
chemical distribution specialty, expanding into government bid business, and
moving into the biotech sector in 1996.&#160;&#160;TeleChem is a market leader
in DNA microarray technology, providing tools and expertise for the explosive
functional genomics and diagnostic screening markets.&#160;&#160;In 2002 and
again in 2003, TeleChem made Inc. Magazine&#8217;s list of the top 500 fastest growing
privately held companies in the USA. In 2005, the Silicon Valley Business
Journal recognized Ms Schena as the President of the 11<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font> largest
woman-owned business enterprise in the Silicon Valley.&#160;&#160;Ms. Schena&#8217;s
long-term contacts in the chemical industry, strong business background and
management expertise are key contributions to TeleChem's
infrastructure.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Mr. Martinsky
</font>, Co-founder of TeleChem International, Inc., previously served as
director of education and consulting at the Codd and Date Consulting
Group.&#160;&#160;Mr. Martinsky has led the ArrayIt Division to play a
significant role in the microarray industry. He has authored several book
chapters and other scientific literature and has become an internationally
recognized lecturer, writer, consultant and teacher.&#160;&#160;In addition to
providing consulting services, Mr. Martinsky has spearheaded ArrayIt&#8217;s technical
support team since 1997.&#160;Along with his daily technical and business
direction of the ArrayIt Product line, Mr. Martinsky established successful
alliances with corporate partners in manufacturing, reagents, equipment and
distribution.&#160;&#160;He is responsible for an educational outreach program
that ensures that the broadly patented ArrayIt Micro Spotting Device is applied
in the field with optimal scientific and technological accuracy. He is currently
serving on the panel that is crafting future regulatory requirements for
microarray manufacturing for the United States Pharmacopeia.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Dr. Schena
</font>is a world-renowned biochemist whose research focuses on microarray
technology, genomics, proteomics, genotyping, molecular diagnostics, and gene
expression.&#160;&#160;Dr. Schena and his colleagues at Stanford University
published the first paper on microarrays in 1995 (Science 270, 467-470),
catalyzing the explosive proliferation of microarray technology at academic and
commercial institutions internationally.&#160;&#160;The 95&#8217; Science paper is the
most highly cited paper in the history of Arabidopsis research and a recent
article in The Scientist places Dr. Schena at positions 1 and 2 on the
&#8220;microarray family tree&#8221;, confirming his role as the founder of microarray
technology and substantiating his status as the Father of Microarray Technology.
More than 20,000 laboratories in 35 countries are using microarrays to explore
basic questions in biology, chemistry, agriculture and medicine, and the
proliferation of the technology has resulted in more than 26,000 publications
since the original 95&#8217; Science publication.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Dr.
Schena&#8217;s success can be traced to an incomparable scientific pedigree. He
trained as a postdoctoral fellow with Dr. Ronald W. Davis in the Department of
Biochemistry at the Beckman Center at Stanford University, and earned a Ph.D.
with Dr. Keith R. Yamamoto in the Department of Biochemistry at UCSF, graduating
first in an exceptional class.&#160; Dr. Schena performed his undergraduate
thesis work with Dr. Daniel E. Koshland, Jr. in the Biochemistry Department at
UC Berkeley, earning a baccalaureate degree with greatest achievement and
highest honors in 1984.&#160; As a professional scientist, he has authored more
than thirty scientific papers and books on subjects ranging from bacteria and
yeast to plants and humans, and has campaigned tirelessly with scientists,
physicians, federal regulatory agencies, granting agencies, and charitable
organizations to promote microarray technology for the betterment of humankind.
Dr. Schena edited the first two books on microarrays, DNA Microarrays: A
Practical Approach by Oxford University Press, and Microarray Biochip Technology
by Eaton Publishing Company, wrote the first microarray textbook Microarray
Analysis for J. Wiley &amp; Sons, and the first book on the proteomic
applications of microarrays entitled Protein Microarrays by Jones &amp;
Bartlett.&#160; Dr. Schena has recently completed a new methods book DNA
Microarrays-Methods Express for Scion Publishing, and continues to lecture
widely, having given more than 120 speeches in 15 countries since 1995. Dr.
Schena was featured as one of the &#8220;Stars of Genomics&#8221; on the NOVA television
special Cracking the Code of Life, which received more than 100,000,000 viewers
worldwide, and is the most highly funded science documentary in United States
history.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Dr.
Schena is currently a Visiting Scholar and Consultant in the ArrayIt&#174; Life
Sciences Division at TeleChem International, Inc.&#160;&#160;Dr. Schena is also
the Chairman of NGS-ArrayIt, Inc and the Founder and President of Mark Schena
Inc., an educational consulting company providing consulting services to a host
of leading organizations such as Affymetrix, <font style="DISPLAY: inline; TEXT-DECORATION: underline">AlphaGene,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">ArrayIt,</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">Biodot,</font> Cartesian
Technologies, Clontech, <font style="DISPLAY: inline; TEXT-DECORATION: underline">diaDexus,</font> General
Scanning, Genomic Solutions, <font style="DISPLAY: inline; TEXT-DECORATION: underline">GSI Lumonics,</font> Incyte
Pharmaceuticals, Irell and Manella, Johnson &amp; Johnson, Morrison &amp;
Foerster, Motorola, Packard Instruments, Perkins Coie, Roche, Synteni,
Technology Mentors, TeleChem International, Wilson Sonsini, Goodrich &amp;
Rosati, and others.&#160;&#160;Dr. Schena resides with Ms. Rene Schena, the
Founder and President of TeleChem International, Inc., in Los Altos,
California.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">Mr. Haje</font>
joined TeleChem in 1999 as the Director of Advertising and Public
Relations.&#160;&#160;He has successfully produced 63 major trade shows in the
USA and Canada, 17 workshops, 11 VIP events, 76 unique full page print
advertising campaigns, 18 direct mail campaigns, e-mail blasts, web site imagery
and two full color company catalogs.&#160;&#160;In 2003, Mr. Haje won the 2003
Signet Advertising Award for Best Full Page Ad in the life sciences
sector.&#160;&#160;Mr. Haje represented the company at the United States Food
and Drug Administration&#8217;s Microarray Quality Control projects I and II, drawing
important attention in the scientific press to the company and its H25K Whole
Human Genome Chip.&#160;&#160;H25K was one of only seven microarray platforms
allowed to participate in the project, including Affymetrix, Agilent, Illumina,
GE Healthcare and Applied BioSystems.&#160;&#160;Mr. Haje has promoted the
ArrayIt brand name through company exposure on prime time television, in cover
stories, feature articles, trade publications, newsletters and web
broadcasts.&#160;&#160;TV includes PBS NOVA, ABC Night Line, CNBC Business
Odyssey.&#160;&#160;He has regularly booked cover stories and feature articles
in Science, The Scientist, Nature, Genetic Engineering News, BioTechniques,
Genome Technology, American Chemical Society, JAMA, PharmaGenomics, Genomics and
Proteomics, BioScience Technology, BioArray News, BioInform, and Genome
Web.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">ITEM
9.01 &#8211; Financial Statements and Exhibits</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Exhibit A: Press Release</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><a name="FIS_SECTION_9_FINANCIAL_STATEMENTS_AND_E" /><a name="FIS_FINANCIAL_STATEMENTS_AND_EXHIBITS">SIGNATURE</a></font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.<a name="DEEP_8K_010808_HTM_SWADDSTYLE" /></font></div>
      <div>
        <table cellpadding="0" cellspacing="0" width="72%">
            <tr>
              <td align="left" valign="top" width="58%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
              <td align="left" valign="top" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="58%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
              <td align="left" valign="top" width="29%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">INTEGRATED
      MEDIA HOLDINGS, INC.</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="58%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
              <td align="left" valign="top" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="58%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
              <td align="left" valign="top" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="58%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
              <td valign="top" width="29%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="58%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Date:&#160;February
      6, 2008</font></div>
              </td>
              <td align="left" valign="top" width="29%" style="BORDER-BOTTOM: black 2px solid">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">By:
      <font style="DISPLAY: inline">&#160;&#160;/s/&#160;William L
      Sklar</font></font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="58%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;
      </font></td>
              <td align="left" valign="top" width="29%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Name:
      William L Sklar</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Title:
      President</font></div>
              </td>
            </tr>
        </table>
      </div><br>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160;
</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman">&#160;
</font></div>
        </div>
      </div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Exhibit
A</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Press
Release</font></div>
      </div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">FOR
IMMEDIATE RELEASE: FEBRUARY 6, 2008</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">Contact:&#160;&#160;&#160;investorinfo@arrayit.com</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="justify"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">Email:
&#160;&#160;&#160;&#160;&#160;investorinfo@arrayit.com</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 13.7pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif">Website:&#160;&#160;&#160;www.Arrayit.com</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 15.95pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Arial, sans-serif">TELECHEM
INTERNATIONAL, INC. COMPLETES BUSINESS COMBINATION WITH INTEGRATED MEDIA
HOLDINGS, INC.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">Houston,
TX &#8211; Integrated Media Holdings, Inc. (OTCBB: <font style="DISPLAY: inline; TEXT-DECORATION: underline">IMHI</font> - <font style="DISPLAY: inline; TEXT-DECORATION: underline">News</font>) today announced
that it has completed the definitive agreement for a business combination via an
acquisition of all outstanding common stock of TeleChem International, Inc.,
(&#8220;Arrayit&#8221;) a pioneer in the biotech market located in Sunnyvale, California.
IMHI&#8217;s board of directors also announced the approval of a 1 for 30 reverse
split. IMHI acquired all the outstanding shares of TeleChem International, Inc.
in exchange for 35,000,000 post-split shares of IMHI as part of the business
combination.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">&#8220;This
business combination of TeleChem International, Inc. is a significant milestone
for IMHI, and is crucial to the future success of the company&#8221;, stated Bill
Sklar, President and CEO of Integrated Media Holdings, Inc. After giving effect
to the reverse split, and prior to the combination with Arrayit, there were
roughly 500,000 outstanding shares. No fractional shares will be issued, and
shareholders will receive cash in lieu of their fractional shares.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">Rene
Schena, Chief Executive Officer of TeleChem International, Inc. stated, &#8220;The
business combination with IMHI is an exciting first step towards development of
our strategic plan for Arrayit. We believe this will greatly enhance our ability
to access capital and further the growth strategy as a leader in the biotech
industry niche that we serve.&#8221;</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">TeleChem
International, Inc. provides products and services to the biotechnology
industry, and is a leader in microarray analysis and print technology, and
operates under the name Arrayit. &#8220;The business combination with IMHI is an
exciting first step towards development of a strategic plan for Arrayit&#8221;, states
Rene Schena, Chief Executive Officer of TeleChem International, Inc. &#8220;We believe
this will enhance our ability to access capital and further the growth strategy
as a leader in the biotech niche we serve&#8221;, Schena stated.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">About
Arrayit</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">TeleChem
International, Inc. is headquartered in the Silicon Valley of California and
operates under the name Arrayit in the biotechnology industry. Arrayit
specializes in empowering the biotech industry by providing unique products and
services to a universal biochemistry platform. Arrayit and its founders are
pioneers of Microarray Analysis and leading providers of trade secret protected
products such as slides, substrates, and accessories. Arrayit has over a decade
of excellence and quality dedicated to meeting the needs of the research and
pharmaceutical industry. Please visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.Arrayit.com</font> for
more information.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Ms. Rene Schena</font>, President and
Founder of TeleChem International, Inc., opened the company in 1993 and moved it
into the biotech sector in &#8217;96. She has led the Company to become a leader in
the DNA microarray technology. Having received awards in 2002 and 2003 from Inc.
Magazine as a top 500 fastest growing privately held companies and in 2005 being
recognized as Silicon Valley Business Journal as the 11<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: super">th</font> largest
woman-owned business in Silicon Valley. Ms.&#160;Schena&#8217;s strong business
background and management expertise are key contributions to TeleChem&#8217;s
infrastructure.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Mr. Todd Matinsky</font> is a
Co-founder and Vice President of the Company and has a deep rooting in education
and consulting. He has led the Arrayit Division since 1997, bringing it to play
a significant role in the microarray industry, establishing successful alliances
and is responsible for an education outreach program that ensures that the
Arrayit Micro Spotting Device is applied in the field with optimal scientific
and technological accuracy.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Dr. Mark Schena</font>,
world-renowned biochemist, is essentially the Father of Microarray Technology.
He and his colleagues at Stanford&#160;University first published a paper on the
technology in 1995. Dr.&#160;Schena&#8217;s credentials are an incomparable scientific
pedigree. Through his years as student, colleague, and teacher, he has worked
with a number of top scientists around the world. Currently, Dr.&#160;Schena is
a Visiting Scholar and Consultant in the Arrayit Life Sciences
Division.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Mr. Paul Haje</font> serves as the
Company&#8217;s Director of Public Relations since 1999. Mr.&#160;Haje is very
accomplished in his field and has aided in developing Arrayit as a viable brand
in the industry. Mr.&#160;Haje won the 2003 Signet Advertising Award for Best
Full Page Ad in the life sciences sector. He has extensive experience in all
areas of advertising and marketing, and has recently represented the Company at
the U.S. FDA&#8217;s Microarray Quality Control Projects I and II.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">About
the Integrated Media Holdings, Inc.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">Integrated
Media Holdings, Inc., headquartered in Houston, Texas, invests in, builds and
operates innovative digital communications and media technologies businesses
that provide multiple forms of distribution for entertainment, media, and
communication services over the Internet and broadband networks. For more
information, please visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.i-mediaholdings.com</font>,
or email <font style="DISPLAY: inline; TEXT-DECORATION: underline">info@i-mediaholdings.com</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Safe Harbor </font><font style="DISPLAY: inline; FONT-STYLE: italic">This news release contains
forward-looking statements. These statements describe management's beliefs and
expectations about the future. We have identified forward-looking statements by
using words such as "expect," "believe," and "should." Although we believe our
expectations are reasonable, our operations involve a number of risks and
uncertainties, and these statements may turn out not to be true. More detailed
information about Integrated Media Holdings, Inc. is available in the Company&#8217;s
public filings with the Securities and Exchange Commission.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 11.4pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
  </body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "form8k.htm", "description": "FORM 8K", "secsgml_size_bytes": 58034}]
{"company-data": {"conformed-name": "Integrated Media Holdings, Inc.", "cik": "0001084507", "assigned-sic": "4899", "irs-number": "760600966", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-16381", "film-number": "08582350"}, "business-address": {"street1": "10 GLENLAKE PARKWAY, SUITE 130", "city": "ATLANTA", "state": "2Q", "zip": "30328", "phone": "678-222-3445"}, "mail-address": {"street1": "10 GLENLAKE PARKWAY, SUITE 130", "city": "ATLANTA", "state": "2Q", "zip": "30328"}, "former-company": [{"former-conformed-name": "Endavo Media & Communications, Inc.", "date-changed": "20040924"}, {"former-conformed-name": "CERISTAR INC", "date-changed": "20021015"}, {"former-conformed-name": "PLANET RESOURCES INC /DE/", "date-changed": "19990915"}]}
form8k.htm
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15 (D)
of
the
SECURITIES
EXCHANGE ACT OF 1934
Date
of Event Reported: February 5, 2008
Date
of Submission: February 6, 2008
INTEGRATED
MEDIA HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
DELAWARE
(State
or other jurisdiction of incorporation or organization)
33-119586
76-0600966
(
Commission File
      Number)
(IRS Employer Identification
      Number
)
William
L. Sklar
President
Integrated Media Holdings,
Inc
.
12000
Westheimer, Ste 340
Houston,
TX 77077-6531
(Address
of principal executive offices)
281-600-6000
Ext 105
(Registrant's
telephone number, including area code)
ITEM
2.01 –Acquisition or Disposition of Assets
On February 5, 2008, Integrated Media
Holdings, Inc. announced that it had signed a definitive merger agreement to
combine with TeleChem International, Inc.("TeleChem").  TeleChem
International is a privately held, Inc. 500 company with diversified business
activities in the life sciences, chemical trading and disease diagnostics
areas.  As a result of the merger, the shareholders of TeleChem (the
"TeleChem Shareholders") will own a majority of the voting stock of Integrated
Media, that will change its name to Arrayit Corporation.
The merger agreement provides that the
shareholders of Telechem International, Inc. will be issued thirty five (35)
million common shares that represent 64.95% of the outstanding common after
taking into account: (i) a 1:30 reverse split approved by the directors and
majority shareholders, (ii) conversion of all outstanding shares of preferred
stock, (iii) conversion of all outstanding debt obligations of Integrated Media;
and (iv) the shares underlying a recently issued warrant to purchase 1,250,000
shares of common stock.
TELECHEM
Description
of the Company
TeleChem
is a privately-held company that was founded in 1993 by Rene Schena and Todd
Martinsky as a chemical import and export trading company.  TeleChem's
chemicals division provides customers with the raw materials required for
plastics, water soluble fertilizers, and alternative fuels.  After
four years of operations in the chemicals market, TeleChem entered the
biotechnology sector with the creation of the ArrayIt® Life Sciences Division in
1996.  Because of the public interest in the Human Genome Project and
microarray technology, TeleChem focused on microarray products and services for
the research, pharmaceutical and diagnostics markets.  TeleChem's
ArrayIt® Division currently provides its patented microarray platform (US
6,101,946) to more than 3,000 installations serving an estimated 10,000
laboratories, making it the most widely used microarray technology in the
world.  Supporting instruments, kits, reagents, and hardware complete
the ArrayIt® line of more than 400 products making up what management believes
is a universal microarray platform for any type of biomolecule.
During
the year 2001, the Diagnostics Division was started in order to leverage the
patented (6,913,879) multi-patient technology for genetic screening and
testing.  This next generation microarray format allows clinical
laboratories to examine tens of thousands of patients on a single microarray,
providing much more cost-effective gene information for population-wide
diagnostics than traditional "single patient" microarrays.  The
company is currently developing or has developed tests for many major human
diseases including cystic fibrosis, sickle cell anemia, and
cancer.  ArrayIt intends to compete in the $20 billion molecular
diagnostics arena.
The
TeleChem customer base includes major universities, pharmaceutical and biotech
companies, agricultural and chemical companies, government agencies, national
research foundations and private sector enterprises around the
world.  The company website receives more than 1,000,000 hits per
month and the Shopping Cart allows on-line product ordering 24 hours a day. The
website makes available the Electronic Library free-of-charge to the tens of
thousands of researchers worldwide that wish to keep pace with the microarray
literature. TeleChem scientists were featured on NOVA's television show
"Cracking the Code of Life" in 2001.  The company received the Rising
Star Award from the City of Sunnyvale in 2002 and 2003, the Silicon Valley Top
50 Award from the San Jose Business Journal in 2003, and consecutive selection
to the Inc. 500 List in 2002 and 2003 by Inc. magazine.
TeleChem's
principal office is in Sunnyvale, California.  TeleChem presently has
eight (8) employees.
Proposed
Executive Officers and Directors After the Acquisition
NAME
AGE
POSITION
Rene'
      A. Schena
44
Chairman
      , Director, President & CEO
Todd
      J. Martinsky
42
Vice
      President & Director
Mark
      Schena, Ph.D.
44
Chief
      Technology Officer, Secretary & Treasurer
Paul
      Haje
52
Director
      of Advertising and Public Relations
Ms.
Schena
holds a degree in Language Studies from the University of
California Santa Cruz. She has 23 years experience in international business,
including translation, contract documentation and commodities trading with a
subsidiary of ConAgra from 1985 to 1988, and as a chemical import and
distribution specialist, department manager, and later President of NuSource
Chemical Corporation.
She
founded TeleChem International, Inc. in 1993, continuing the import and export
chemical distribution specialty, expanding into government bid business, and
moving into the biotech sector in 1996.  TeleChem is a market leader
in DNA microarray technology, providing tools and expertise for the explosive
functional genomics and diagnostic screening markets.  In 2002 and
again in 2003, TeleChem made Inc. Magazine's list of the top 500 fastest growing
privately held companies in the USA. In 2005, the Silicon Valley Business
Journal recognized Ms Schena as the President of the 11
th
largest
woman-owned business enterprise in the Silicon Valley.  Ms. Schena's
long-term contacts in the chemical industry, strong business background and
management expertise are key contributions to TeleChem's
infrastructure.
Mr. Martinsky
, Co-founder of TeleChem International, Inc., previously served as
director of education and consulting at the Codd and Date Consulting
Group.  Mr. Martinsky has led the ArrayIt Division to play a
significant role in the microarray industry. He has authored several book
chapters and other scientific literature and has become an internationally
recognized lecturer, writer, consultant and teacher.  In addition to
providing consulting services, Mr. Martinsky has spearheaded ArrayIt's technical
support team since 1997. Along with his daily technical and business
direction of the ArrayIt Product line, Mr. Martinsky established successful
alliances with corporate partners in manufacturing, reagents, equipment and
distribution.  He is responsible for an educational outreach program
that ensures that the broadly patented ArrayIt Micro Spotting Device is applied
in the field with optimal scientific and technological accuracy. He is currently
serving on the panel that is crafting future regulatory requirements for
microarray manufacturing for the United States Pharmacopeia.
Dr. Schena
is a world-renowned biochemist whose research focuses on microarray
technology, genomics, proteomics, genotyping, molecular diagnostics, and gene
expression.  Dr. Schena and his colleagues at Stanford University
published the first paper on microarrays in 1995 (Science 270, 467-470),
catalyzing the explosive proliferation of microarray technology at academic and
commercial institutions internationally.  The 95' Science paper is the
most highly cited paper in the history of Arabidopsis research and a recent
article in The Scientist places Dr. Schena at positions 1 and 2 on the
"microarray family tree", confirming his role as the founder of microarray
technology and substantiating his status as the Father of Microarray Technology.
More than 20,000 laboratories in 35 countries are using microarrays to explore
basic questions in biology, chemistry, agriculture and medicine, and the
proliferation of the technology has resulted in more than 26,000 publications
since the original 95' Science publication.
Dr.
Schena's success can be traced to an incomparable scientific pedigree. He
trained as a postdoctoral fellow with Dr. Ronald W. Davis in the Department of
Biochemistry at the Beckman Center at Stanford University, and earned a Ph.D.
with Dr. Keith R. Yamamoto in the Department of Biochemistry at UCSF, graduating
first in an exceptional class.  Dr. Schena performed his undergraduate
thesis work with Dr. Daniel E. Koshland, Jr. in the Biochemistry Department at
UC Berkeley, earning a baccalaureate degree with greatest achievement and
highest honors in 1984.  As a professional scientist, he has authored more
than thirty scientific papers and books on subjects ranging from bacteria and
yeast to plants and humans, and has campaigned tirelessly with scientists,
physicians, federal regulatory agencies, granting agencies, and charitable
organizations to promote microarray technology for the betterment of humankind.
Dr. Schena edited the first two books on microarrays, DNA Microarrays: A
Practical Approach by Oxford University Press, and Microarray Biochip Technology
by Eaton Publishing Company, wrote the first microarray textbook Microarray
Analysis for J. Wiley & Sons, and the first book on the proteomic
applications of microarrays entitled Protein Microarrays by Jones &
Bartlett.  Dr. Schena has recently completed a new methods book DNA
Microarrays-Methods Express for Scion Publishing, and continues to lecture
widely, having given more than 120 speeches in 15 countries since 1995. Dr.
Schena was featured as one of the "Stars of Genomics" on the NOVA television
special Cracking the Code of Life, which received more than 100,000,000 viewers
worldwide, and is the most highly funded science documentary in United States
history.
Dr.
Schena is currently a Visiting Scholar and Consultant in the ArrayIt® Life
Sciences Division at TeleChem International, Inc.  Dr. Schena is also
the Chairman of NGS-ArrayIt, Inc and the Founder and President of Mark Schena
Inc., an educational consulting company providing consulting services to a host
of leading organizations such as Affymetrix,
AlphaGene,
ArrayIt,
Biodot,
Cartesian
Technologies, Clontech,
diaDexus,
General
Scanning, Genomic Solutions,
GSI Lumonics,
Incyte
Pharmaceuticals, Irell and Manella, Johnson & Johnson, Morrison &
Foerster, Motorola, Packard Instruments, Perkins Coie, Roche, Synteni,
Technology Mentors, TeleChem International, Wilson Sonsini, Goodrich &
Rosati, and others.  Dr. Schena resides with Ms. Rene Schena, the
Founder and President of TeleChem International, Inc., in Los Altos,
California.
Mr. Haje
joined TeleChem in 1999 as the Director of Advertising and Public
Relations.  He has successfully produced 63 major trade shows in the
USA and Canada, 17 workshops, 11 VIP events, 76 unique full page print
advertising campaigns, 18 direct mail campaigns, e-mail blasts, web site imagery
and two full color company catalogs.  In 2003, Mr. Haje won the 2003
Signet Advertising Award for Best Full Page Ad in the life sciences
sector.  Mr. Haje represented the company at the United States Food
and Drug Administration's Microarray Quality Control projects I and II, drawing
important attention in the scientific press to the company and its H25K Whole
Human Genome Chip.  H25K was one of only seven microarray platforms
allowed to participate in the project, including Affymetrix, Agilent, Illumina,
GE Healthcare and Applied BioSystems.  Mr. Haje has promoted the
ArrayIt brand name through company exposure on prime time television, in cover
stories, feature articles, trade publications, newsletters and web
broadcasts.  TV includes PBS NOVA, ABC Night Line, CNBC Business
Odyssey.  He has regularly booked cover stories and feature articles
in Science, The Scientist, Nature, Genetic Engineering News, BioTechniques,
Genome Technology, American Chemical Society, JAMA, PharmaGenomics, Genomics and
Proteomics, BioScience Technology, BioArray News, BioInform, and Genome
Web.
ITEM
9.01 – Financial Statements and Exhibits
Exhibit A: Press Release
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
INTEGRATED
      MEDIA HOLDINGS, INC.
Date: February
      6, 2008
By:
/s/ William L
      Sklar
Name:
      William L Sklar
Title:
      President
Exhibit
A
Press
Release
FOR
IMMEDIATE RELEASE: FEBRUARY 6, 2008
Contact:   investorinfo@arrayit.com
Email:
     investorinfo@arrayit.com
Website:   www.Arrayit.com
TELECHEM
INTERNATIONAL, INC. COMPLETES BUSINESS COMBINATION WITH INTEGRATED MEDIA
HOLDINGS, INC.
Houston,
TX – Integrated Media Holdings, Inc. (OTCBB:
IMHI
-
News
) today announced
that it has completed the definitive agreement for a business combination via an
acquisition of all outstanding common stock of TeleChem International, Inc.,
("Arrayit") a pioneer in the biotech market located in Sunnyvale, California.
IMHI's board of directors also announced the approval of a 1 for 30 reverse
split. IMHI acquired all the outstanding shares of TeleChem International, Inc.
in exchange for 35,000,000 post-split shares of IMHI as part of the business
combination.
"This
business combination of TeleChem International, Inc. is a significant milestone
for IMHI, and is crucial to the future success of the company", stated Bill
Sklar, President and CEO of Integrated Media Holdings, Inc. After giving effect
to the reverse split, and prior to the combination with Arrayit, there were
roughly 500,000 outstanding shares. No fractional shares will be issued, and
shareholders will receive cash in lieu of their fractional shares.
Rene
Schena, Chief Executive Officer of TeleChem International, Inc. stated, "The
business combination with IMHI is an exciting first step towards development of
our strategic plan for Arrayit. We believe this will greatly enhance our ability
to access capital and further the growth strategy as a leader in the biotech
industry niche that we serve."
TeleChem
International, Inc. provides products and services to the biotechnology
industry, and is a leader in microarray analysis and print technology, and
operates under the name Arrayit. "The business combination with IMHI is an
exciting first step towards development of a strategic plan for Arrayit", states
Rene Schena, Chief Executive Officer of TeleChem International, Inc. "We believe
this will enhance our ability to access capital and further the growth strategy
as a leader in the biotech niche we serve", Schena stated.
About
Arrayit
TeleChem
International, Inc. is headquartered in the Silicon Valley of California and
operates under the name Arrayit in the biotechnology industry. Arrayit
specializes in empowering the biotech industry by providing unique products and
services to a universal biochemistry platform. Arrayit and its founders are
pioneers of Microarray Analysis and leading providers of trade secret protected
products such as slides, substrates, and accessories. Arrayit has over a decade
of excellence and quality dedicated to meeting the needs of the research and
pharmaceutical industry. Please visit
www.Arrayit.com
for
more information.
Ms. Rene Schena
, President and
Founder of TeleChem International, Inc., opened the company in 1993 and moved it
into the biotech sector in '96. She has led the Company to become a leader in
the DNA microarray technology. Having received awards in 2002 and 2003 from Inc.
Magazine as a top 500 fastest growing privately held companies and in 2005 being
recognized as Silicon Valley Business Journal as the 11
th
largest
woman-owned business in Silicon Valley. Ms. Schena's strong business
background and management expertise are key contributions to TeleChem's
infrastructure.
Mr. Todd Matinsky
is a
Co-founder and Vice President of the Company and has a deep rooting in education
and consulting. He has led the Arrayit Division since 1997, bringing it to play
a significant role in the microarray industry, establishing successful alliances
and is responsible for an education outreach program that ensures that the
Arrayit Micro Spotting Device is applied in the field with optimal scientific
and technological accuracy.
Dr. Mark Schena
,
world-renowned biochemist, is essentially the Father of Microarray Technology.
He and his colleagues at Stanford University first published a paper on the
technology in 1995. Dr. Schena's credentials are an incomparable scientific
pedigree. Through his years as student, colleague, and teacher, he has worked
with a number of top scientists around the world. Currently, Dr. Schena is
a Visiting Scholar and Consultant in the Arrayit Life Sciences
Division.
Mr. Paul Haje
serves as the
Company's Director of Public Relations since 1999. Mr. Haje is very
accomplished in his field and has aided in developing Arrayit as a viable brand
in the industry. Mr. Haje won the 2003 Signet Advertising Award for Best
Full Page Ad in the life sciences sector. He has extensive experience in all
areas of advertising and marketing, and has recently represented the Company at
the U.S. FDA's Microarray Quality Control Projects I and II.
About
the Integrated Media Holdings, Inc.
Integrated
Media Holdings, Inc., headquartered in Houston, Texas, invests in, builds and
operates innovative digital communications and media technologies businesses
that provide multiple forms of distribution for entertainment, media, and
communication services over the Internet and broadband networks. For more
information, please visit
www.i-mediaholdings.com
,
or email
info@i-mediaholdings.com
Safe Harbor
This news release contains
forward-looking statements. These statements describe management's beliefs and
expectations about the future. We have identified forward-looking statements by
using words such as "expect," "believe," and "should." Although we believe our
expectations are reasonable, our operations involve a number of risks and
uncertainties, and these statements may turn out not to be true. More detailed
information about Integrated Media Holdings, Inc. is available in the Company's
public filings with the Securities and Exchange Commission.